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ABSTRACT
Background. Intermittent smoking is prevalent amongHispa-
nics, but little is known about whether this smoking pattern
associates with increased chronic kidney disease (CKD) risk
in this population. The objective of the present study is to
identify patterns of exposure associated with CKD in US
Hispanics.
Methods.We used cross-sectional data on 15 410 participants
of the Hispanics Community Health Study/the Study of Lati-
nos, a population-based study of individuals aged 18–74
years, recruited in 2008 to 2011 from four US field centers
(Bronx, NY; Chicago, IL; Miami, FL; San Diego, CA). Smoking
exposure was obtained through a questionnaire. CKD was de-
fined by an estimated glomerular filtration rate of <60 mL/min/
1.73 m2 or a urine albumin-to-creatinine ratio of ≥30 mg/g.
Results. Approximately 14% of individuals were daily and 7%
were intermittent smokers, and 16% were past smokers. There
was a significant interaction between smoking status and pack-
years of exposure (P = 0.0003). In adjusted models, there was an
increased odds of CKD among daily, intermittent and past
smokers by pack-years compared with never smokers. The
association of intermittent smokers was significant at 10
pack-years [odds ratio (OR) = 1.38, 95% confidence intervals
(CI) 1.06, 1.81], whereas for daily smokers this association
was observed at 40 pack-years (OR = 1.43, 95% CI 1.09, 1.89).
Conclusions. Our findings of increased risk of CKD among
Hispanics who are intermittent smokers support screening
and smoking cessation interventions targeted to this population
for the prevention of CKD. It also suggests novel mechanistic
pathways for kidney toxicity that should be further explored
in future studies.
Keywords: chronic kidney disease, Hispanics/Latinos, inter-
mittent smoking
INTRODUCTION
Epidemiologic studies have shown that smoking is associated
with reduced kidney function [1–3], development of microal-
buminuria and clinical proteinuria [4–6], and progression to
end-stage kidney disease (ESKD) [7]. Adding to this evidence,
a recent study showed an excess of death due to renal disease
attributable to current smoking [8]. Among smokers, mortality
due to renal failure was increased by 2-fold, and death due
to essential hypertension and hypertensive renal disease was
increased by 2.4- to 2.6-fold [8]. Smoking is associated with
atherosclerotic vascular disease [9–12] and metabolic syndrome
[13]; both conditions are also known risk factors for chronic
kidney disease (CKD). Experimental evidence suggests that
smoking promotes endothelial dysfunction, oxidative stress
and inflammation [14–18]. Nicotine has been shown to worsen
the severity of kidney injury in animal models of diabetes [19]
and acute nephritis [16]. Nicotine promotes mesangial cell pro-
liferation and hypertrophy via nonneuronal nicotinic acetylcho-
line receptors [20] and podocyte injury in cell culture (L. Raij,
personal communication). Overall, the evidence supports bio-
logic mechanisms linking smoking to CKD causally.
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Although smoking prevalence has declined in the US popu-
lation [21], the rates of smoking among Hispanics/Latinos are
higher compared with national averages, particularly among in-
dividuals of Puerto Rican and Cuban backgrounds [22, 23].
Hispanics also have a high prevalence of intermittent smoking
compared with other racial/ethnic groups [24, 25]. Prior studies
have shown the association of smoking duration and total
smoking exposure on CKD [26–28]. However, these studies
have not accounted for the effects of regular versus intermittent
exposures on CKD risk or fully characterized the risk among
past smokers, which have shown either a reduction or no
CKD risk after smoking cessation [26, 28, 29].
We hypothesized that, among Hispanics, patterns of expos-
ure among current smokers, in addition to total smoking
exposure, explain the association of smoking with CKD. The
characterization of harmful effects of smoking at lower levels
of exposure in this population is important as this information
could inform public health preventive programs and clinicians
in their effort to reduce the burden of CKD. Here, we describe
important interactions between smoking status and cumulative
smoking exposure in Hispanics/Latino individuals, the largest
minority population in the USA, who were part of the Hispa-
nics Community Health Study/the Study of Latinos (HCHS/
SOL).
MATERIALS AND METHODS
Study population
This is a cross-sectional study of the HCHS/SOL, a
population-based cohort study of 16 415 self-identified
Hispanics/Latino persons aged 18–74 years at the time of screen-
ing from four US field centers (Bronx, NY; Chicago, IL; Miami,
FL; San Diego, CA) [30]. The cohort includes participants
who self-identified as having Hispanics/Latino background, the
largest groups being Central American (n = 1730), Cuban (n =
2348), Dominican (n = 1460), Mexican (n = 6471), Puerto
Rican (n = 2728) and South American (n = 1068). The baseline
examination during the period of 2008–11 included a clinical
visit with comprehensive biological, behavioral and socio-
demographic assessments [30]. The sample design and cohort
selection have been described previously [31]. Briefly, a stratified
two-stage area probability sample of households was selected in
each of the four field centers. The first sampling stage randomly
selected census block groups with stratification based on
Hispanics/Latino concentration and proportion of high/low
socioeconomic status. The second sampling stage randomly se-
lected households, with stratification, from US Postal Service
registries that covered the randomly selected census block
groups. Both stages oversampled certain strata to increase the
likelihood that a selected address yielded a Hispanics/Latino
household. After households were sampled, in-person or tele-
phone contacts were made to screen eligible households and
to roster its members. Lastly, the study oversampled the 45–74
age group (n = 9714, 59.2%) to facilitate examination of target
outcomes. This study is based on cross-sectional analysis of
baseline visit exposures and outcomes. All data were obtained
during a clinical visit, which included a physical exam, collection
of biospecimens (urine, blood) and administration of a ques-
tionnaire for lifestyle and clinical measures [30]. The study
was approved by the Institutional Review Boards at the coord-
inating center and each field center where all subjects gave writ-
ten consent. Informed consent was obtained for all participants.
The study adheres to the principles of the Declaration of
Helsinki.
Anthropometrics and blood pressure were obtained using
standardized protocols during a clinical visit, in addition to
blood and urine samples for bioassays. Creatinine was mea-
sured in serum and urine on a Roche Modular P Chemistry
Analyzer (Roche Diagnostics Corporation, Indianapolis, IN,
USA) using a creatinase enzymatic method (Roche Diagnostics
Corporation). Serum and urine creatinine measurements are
traceable to isotope dilutionmass spectrometry reference meas-
urement procedures. Albumin was measured in urine using an
immunoturbidimetric method on the ProSpec nephelometric
analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY,
USA, formerly Dade Behring). Serum cystatin C was measured
using a turbidimetric method on the Roche Modular P Chem-
istry Analyzer (Gentian AS, Moss, Norway).
Exposures
Self-reported tobacco exposure was defined as current, past
or never smoking from information collected through ques-
tionnaires based on the following questions: ‘Have you ever
smoked at least 100 cigarettes in your entire life?’ Participants
responding ‘yes’ were then asked if they now smoke daily
(daily smokers), some days (intermittent smokers) or not at
all (former smokers). Tobacco use measures included age first
started to smoke cigarettes regularly, number of years smoked
cigarettes, and, on average, number of cigarettes per day. Life-
time pack-years was used as an estimate of long-term exposure
of cigarette smoking and calculated based on age at smoking
initiation, periods of quitting and average lifetime cigarettes
per day, as the average number of packs of cigarettes smoked
per day multiplied by the number of years smoked. The repro-
ducibility of smoking variables was assessed in a sample of
56 individuals through repeated study visits (kappa = 0.93 for
smoking status, reliability coefficients of 0.89, 0.92 and 0.83
for age started smoking, current cigarettes/day and lifetime
average cigarettes a day, respectively) [22].
Outcomes
CKD was defined based on a composite outcome that
included an estimated glomerular filtration rate (eGFR) of <60
mL/min/1.73m2 (Stage 3 CKD) or a urine albumin-to-creatinine
ratio (UACR) of ≥30 mg/g. eGFR was estimated using the equa-
tion developed by the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) working group, which includes
serum creatinine, age, sex and race components [32–34]. We
also calculated eGFR using the CKD-EPI equation based on
serum creatinine and cystatin C, but results were unchanged.
Therefore, we reported CKD based on serum creatinine eGFR.
The CKD-EPI equations have recently been shown to more ac-
curately estimate ESKD and mortality risk than did the Modifi-
cation of Diet in Renal Disease equation [32]; however, these
eGFR equations have not been validated in Hispanics.
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Statistical analysis
For the descriptive analysis, the mean and the 95% confi-
dence interval (CI) were generated for quantitative variables
with normal distributions. The median and the interquartile
range were generated for the continuous variables, which
were not normally distributed. For categorical variables, the col-
umn percentages and 95% CI were presented. We applied
survey logistic regression to study the association between the
smoking exposure and a CKD composite outcome. This pro-
cedure was used to account for the complex study design as pre-
viously reported [30]. We tested the interaction between
smoking status and cumulative pack-years, age and sex at the
significance level of 0.05. We also tested models using an indi-
cator variable for blood pressure lowering medications includ-
ing angiotensin-converting enzyme inhibitor and angiotensin
II receptor blockers. The final models were adjusted for age,
sex, body mass index, history of diabetes, history of prevalent
coronary heart disease, systolic blood pressure, history of alco-
hol intake, high- and low-density lipoprotein cholesterols,
hypertension, and cross-classification of center and Hispanics/
Latino background group, and included the interaction between
smoking status and cumulative pack-years. Education was not
significantly associated with CKD, and it was not included in
the final models. The adjusted prevalence of CKD was esti-
mated based on survey logistic regression estimates using
predicted marginal results for the subgroups of current daily
smokers, intermittent smokers, past smokers and never smo-
kers, adjusting to the distribution of target population of
other covariates. We then estimated the odds ratios (OR) of
CKD for smokers (current daily, intermittent and past) relative
to never smokers across levels of cumulative smoking in pack-
years. All reported measures were weighted to account for the
complex sampling design. OR and 95% CI were reported. All
analyses were performed using SAS 9.3 software (SAS Institute,
Cary, NC, USA) and SUDAAN software release 11 (RTI Inter-
national, Research Triangle Park, NC, USA).
RESULTS
The characteristics of the HCHS/SOL target population by
smoking exposure are shown in Table 1. Approximately 21%
of individuals reported current smoking, of which 14% re-
ported daily smoking, and 7% reported intermittent smoking,
and 16% were past smokers. Intermittent smokers had lower
mean pack-years smoking exposure and smoking years than
those reporting daily or past smoking. In addition, they were
younger, more often men (except when compared with past
smokers) and had a lower prevalence of comorbidities com-
pared with never smokers and the other smoker groups, except
for history of cardiovascular disease, which was least prevalent
among never smokers. Themean eGFR was comparable among
intermittent smokers and never smokers, while the median
UACR was similar between current daily smokers and never
smokers.
Among Hispanics/Latinos meeting our criteria of CKD, 17%
had an eGFRof <60mL/min/1.73m2, 73% hadUACR≥30mg/g
and 10% had both reduced eGFR and increased UACR. CKD
prevalences among daily smokers, intermittent smokers, past
smokers and never smokers were 10, 9, 13 and 10%, respectively.
Table 1. Descriptive characteristics by smoking exposure: the HCHS/SOL: 2008–11
Characteristic Smoking exposure
Daily smoker Intermittent smoker Past smoker Never smoker
Mean/
percent
(95% CI) Mean/
percent
(95% CI) Mean/
percent
(95% CI) Mean/
percent
(95% CI)
Unweighted sample size 2023 897 2887 9603
Mean cigarette pack-years 18.3 (16.7, 19.8) 5.2 (4.3, 6.1) 13.6 (12.6, 14.7) 0.0 (0.0, 0.0)
Mean age, years 42.6 (41.6, 43.6) 35.7 (34.4, 36.9) 48.3 (47.4, 49.2) 39.5 (38.9, 40.0)
Female sex, % 40.8 (37.9, 43. 8) 39.8 (33.7, 46.2) 39.1 (36.6, 41.7) 60.5 (59.1, 61.9)
Mean BMI, kg/m2 28.8 (28.4, 29.2) 29.5 (28.5, 30.5) 30.3 (29.9, 30.7) 29.2 (29.0, 29.4)
ACE inhibitors, % 8.2 (7.0, 10.0) 4.0 (2.8, 5.8) 14.7 (12.9, 16.8) 7.5 (6.8, 8.3)
Angiotensin II receptor antagonists, % 2.4 (1.7, 3.8) 2.1 (1.1, 4.0) 5.2 (4.3, 6.4) 3.3 (2.9, 3.8)
Diabetes, % 12.6 (11.0, 14.4) 11.5 (8.8, 14.9) 21.5 (19.6, 23.6) 13.3 (12.4, 14.3)
History of CVD, % 5.6 (4.5, 6.9) 5.8 (3.3, 9.9) 6.1 (4.9, 7.5) 3.7 (3.15, 4.24)
Hypertension, % 21. 7 (19.2, 24.3) 13.0 (10.3, 16.4) 32.2 (29.6, 34.9) 19.7 (18.5, 21.0)
Mean systolic blood pressure 120.7 (119. 7, 121.8) 117.4 (115.7, 119.1) 123.6 (122.7, 124.5) 118.8 (118.2, 119.4)
Mean diastolic blood pressure 72.8 (72.1, 73.6) 71.1 (70.0, 72.2) 73.8 (73.2, 74.3) 71.6 (71.2, 72.0)
Alcohol, %
Current 11.6 (9.9, 13.5) 5.3 (3.7, 7.6) 11.3 (9.7, 13.2) 23.8 (22.0, 25.7)
Past 27.9 (25.3, 30.6) 16.6 (13.3, 20.4) 36.1 (33.3, 38.9) 30.5 (28.8, 32.2)
Never 60.5 (57.7, 63.3) 78.1 (73.5, 82.1) 52.6 (49.6, 55.6) 45.7 (43.8, 47.6)
Mean HDL cholesterol, mg/g 46.8 (46.0, 47.7) 48.0 (46.8, 49.3) 48.0 (47.3, 48.7) 49.6 (49.2, 50.0)
Mean LDL cholesterol, mg/g 120.0 (117.7, 122.2) 118.0 (114.6, 121.4) 126.6 (124.6, 128.5) 118.2 (117.0, 119.3)
Mean eGFRcr, mL/min/1.73 m2 97.5 (96.4, 98.6) 103.2 (101.4, 105.0) 93.7 (92.5, 94.9) 102.3 (101.6, 103.0)
Smoking years 24.6 (23.6, 25.6) 15.3 (14.1, 16.6) 17.2 (16.5, 17.9) 0
Median UACR (IQR), mg/g 6.0 (4.2, 10.0) 5.5 (4.0, 8.9) 6.2 (4.2, 11.5) 6.1 (4.3, 10.8)
BMI, body mass index; ACE, angiotensin-converting enzyme; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFRcr, estimated glomerular
filtration rate based on serum creatinine; UACR, urine albumin-to-creatinine ratio; IQR, interquartile range.
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The survey-adjusted prevalence estimate of CKD by smoking
categories was 8% for daily smokers (95% CI 7, 10), 12% for
intermittent smokers (9, 15), 11% for past smokers (9, 12) and
10% for never smokers (9, 11).
There was a significant interaction between smoking
status (daily and intermittent, past compared to never) with
pack-years of exposure (P = 0.0003) on CKD risk. Based on
the model that accounted for this interaction and adjusted
for other CKD risk factors, we calculated the OR associated
with smoking at 10, 20 and 40 pack-years of smoking for
daily and past smokers, and at 5, 10 and 20 pack-years for inter-
mittent smokers compared with never smokers (Table 2).
Lower numbers of pack-years were chosen for intermittent
smokers because that group had lower cumulative smoking
exposure.
Daily and intermittent smokers showed an increase in the
odds of CKD compared with never smokers with increasing
pack-years of exposure, but intermittent smokers had a steeper
increase (Figure 1). For example, with 20 pack-years, intermit-
tent smoking was associated with an 80% higher odds of CKD
compared with never smokers, whereas daily smokers had a
non-significant 3% higher odds of CKD (Table 2). In addition,
the association for intermittent smoking was statistically signifi-
cant at 10 pack-years of smoking, whereas for daily smokers this
association was observed only at 40 pack-years.
The OR comparing past smokers with never smokers
increased linearly across pack-years of exposure at a very low
rate, and it was not significant (Figure 1). We also tested the
association of time since quitting smoking and CKD among
past smokers in models replacing pack-years with this time vari-
able, but the association was not significant. In addition, there
was no interaction of smoking categories with age (P = 0.06) or
sex (P = 0.69) on the risk of CKD.
DISCUSSION
Ourmain findings are the significant interactions among smok-
ing status and cumulative pack-year exposure in Hispanics/
Table 2. Adjusted ORa and 95% CI of CKD by smoking categories and
pack-years
OR 95% CI
Estimation for daily smokers
Daily smokers with 10 pack-years 0.87 (0.71, 1.07)
Daily smokers with 20 pack-years 1.03 (0.85, 1.25)
Daily smokers with 40 pack-years 1.43 (1.09, 1.89)
Estimation for intermittent smokers
Intermittent smokers with 5 pack-years 1.21 (0.92, 1.58)
Intermittent smokers with 10 pack-years 1.38 (1.06, 1.81)
Intermittent smokers with 20 pack-years 1.81 (1.24, 2.65)
Estimation for past smokers
Past smokers with 5 pack-years 1.17 (0.98, 1.39)
Past smokers with 10 pack-years 1.19 (1.00, 1.42)
Past smokers with 20 pack-years 1.23 (0.96, 1.57)
aOR of CKD associated with smoking (daily, intermittent and past) compared with never
smokers by pack-years of smoking based on models adjusted for age, sex,
cross-classification of center and Hispanics/Latino background, body mass index, history
of diabetes, history of prevalent coronary heart disease, systolic blood pressure, history of
alcohol intake, high- and low-density lipoprotein cholesterols, hypertension and blood
pressure lowering medications including angiotensin-converting enzyme inhibitors and
angiotensin II receptor blockers. P-value for interaction of smoking categories with
pack-years = 0.0003.
F IGURE 1 : Distribution of cumulative pack-years by smoker group among Hispanics/Latinos. The histogram shows the percent of cigarette
pack-year groups (0–10, 10–20 and so on) by smoker groups (current daily, intermittent and past smokers). Lines are the adjusted OR of CKD by
smoker groups (current daily, intermittent and past versus never smokers) (see Table 2 for covariates). The x-axis uses the midpoint of the cigarette
pack-year group interval.
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Latino individuals, which have not been previously reported.
Current smokers showed increased odds of CKD associated
with higher level of cumulative pack-years of exposure com-
pared with never smokers, in agreement with prior studies
[26–28]. Our new findings are related to a subset of current
smokers who had an intermittent pattern of smoking, which
is more common among Hispanics populations [24]. Although
these individuals had low mean cumulative pack-years, were
younger and had fewer overall risk factors for CKD, their
odds of CKD compared with never smokers were higher than
daily smokers across various pack-year levels (Table 2, Figure 1).
These findings suggest that intermittent smoking exposure has
deleterious effects in the kidneys, themechanisms of whichmay
differ from those related to daily smoking patterns. Given users
of nicotine delivery devices such as e-cigarettes, estimated as
3–7%of theUS population, often continue smoking intermittent-
ly [35–38], these findings could be relevant to this population.
However, our study does not have information on e-cigarette
use, and this issue will need to be addressed in future studies.
Mechanisms related to CKD in intermittent smokers include
transitory increases in blood pressure due to acute vascular
effects of smoking [39, 40]. Blood pressure variability has been
previously associated with kidney organ damage including
CKD among hypertensive individuals [41]. In addition to hemo-
dynamic changes, intermittent exposure of the kidney to toxic
compounds present in cigarettes may also play a role in CKD.
Experimental research suggests that nicotine stimulates mesan-
gial cell proliferation and hypertrophy [20], inflammation and
atherosclerosis [18], and induces oxidative stress pathways,
which could promote kidney damage. Cadmium, a pollutant pre-
sent in tobacco smoking, accumulates in kidneys and has been
associated with hypertension [42]. Chronic smoking exposure
induces enzymes related to the metabolism and excretion of
nicotine and cadmium, potentially reducing their circulating
levels and acute tissue toxicity. Therefore, intermittent smokers
could be exposed to a higher level of these toxins acutely,
although the exposure may be for a short period. In the
HCHS/SOL study, intermittent smokers more often were men
ofMexican background [22], althoughwe did not find significant
differences in the observed association between smoking and
CKD by sex, and we accounted for Hispanics/Latino background.
Future work is needed to identify causal pathways relating inter-
mittent smoking patterns to CKD.
The pattern of risk for past smokers was constant across
cumulative pack-years, with an ∼20% higher odds of CKD
compared with never smokers, regardless of the time since quit-
ting. Although not significant, these findings suggest a remain-
ing residual risk of CKD among individuals who quit smoking.
Our findings are in agreement with prior studies that showed a
lower risk of CKD among past smokers, but we did not observe
a lack of risk among past smokers, which suggests that smoking
exposure has a long-lasting harmful effect on kidneys.
This is the largest study of Hispanics/Latinos to examine the
relationship of smoking exposure patterns—including daily
and intermittent smoking—with CKD risk. Our study is limited
to cross-sectional analyses, and therefore no causal inferences
should be drawn. We also lack data on secondhand smoke ex-
posure and the question of whether intermittent smokers
maintain the smoking habit over their entire life. Ongoing
HCHS/SOL follow-up visits will allow the study of these asso-
ciations prospectively. Most of the CKD cases in our composite
outcome were due to increased albuminuria, which is the most
common manifestation of CKD, particularly in a young popu-
lation such as the HCHS/SOL target population. Microalbumi-
nuria is a strong and independent predictor of ESKD and
cardiovascular health outcomes [43, 44].
Our findings suggest that intermittent smoking exposure is
associated with an increased odds of CKD. These findings have
important implications for public health, especially forHispanics
who have a high prevalence of intermittent smoking, estimated at
30% in the National Health and Nutrition Examination Survey
1999–2000 and 2001–2 [24]. This intermittent pattern may be
unrecognized by healthcare providers, thereby missing oppor-
tunities for prevention. Our findings support public health
efforts to avoid smoking exposure [45], particularly among
young populations such as Hispanics/Latinos. Future studies
should examine the relationship of secondhand smoke exposure
to CKD risk in addition to the effect of intermittent smoking
among e-cigarette users on CKD outcomes.
CONCLUSIONS
Our study shows significant associations of current smoking
with CKD across increasing cumulative smoking exposure
(pack-years) among Hispanics/Latinos, which was significant
among intermittent smokers at lower pack-years of smoking.
There was a remaining non-significant risk of CKD among
past smokers even years after quitting smoking, which could re-
flect prior damage or continuous exposure through passive
smoking. Further work is needed to identify the mechanisms
associated with these findings and the risk of secondhand and
active intermittent smoking exposure on CKD, and in addition
to determine the temporal relationship of these associations
using longitudinal data. Our research supports efforts to target
intermittent smoking exposure among Hispanics/Latinos
through public health interventions and extend these current
recommendations to CKD outcomes.
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demonstrates up-regulated miR-422a driving reduction of
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ABSTRACT
Background.Aberrancies in gene expression in immune effect-
or cells and in end-organs are implicated in lupus pathogenesis.
To gain insights into the mechanisms of tissue injury, we pro-
filed the expression of micro-RNAs in inflammatory kidney
lesions of human lupus nephritis (LN).
Methods. Kidney specimens were from patients with active
proliferative, membranous or mixed LN and unaffected control
tissue. Micro-RNAs were quantified by TaqMan Low Density
Arrays. Bioinformatics was employed to predict gene targets,
gene networks and perturbed signaling pathways. Results
were validated by transfection studies (luciferase assay, real-
time PCR) and in murine LN. Protein expression was deter-
mined by immunoblotting and immunohistochemistry.
Results. Twenty-four micro-RNAs were dysregulated (9 up-
regulated, 15 down-regulated) in human LN compared with
control renal tissue. Their predicted gene targets participated
in pathways associated with TGF-β, kinases, NF-κB, HNF4A,
Wnt/β-catenin, STAT3 and IL-4. miR-422a showed the high-
est upregulation (17-fold) in active LN and correlated with fi-
brinoid necrosis lesions (β = 0.63, P = 0.002). In transfection
studies, miR-422a was found to directly target kallikrein-related
peptidase 4 (KLK4) mRNA. Concordantly, KLK4 mRNA was
significantly reduced in the kidneys of human and murine LN
and correlated inversely with miR-422a levels. Immunohisto-
chemistry confirmed reduced KLK4 protein expression in
renal mesangial and tubular epithelial cells in human and mur-
ine LN.
Conclusions. KLK4, a serine esterase with putative renoprotec-
tive properties, is down-regulated by miR-422a in LN kidney
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